BioSpace News Archive

BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, today announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody.

Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra.

The Coretec Group, Inc., (OTCQB: CRTG) (the “Company”) has partnered with The University of Adelaide, one of the global top universities in the field of applied glass science and photonics, to develop a glass to be used in The Coretec Group’s CSpace, a 3D static volumetric display technology.

Xencor, Inc. today announced 2022 corporate priorities and anticipated clinical development and research milestones.

Cambrex recently celebrated the 40th anniversary of its founding in 1981.

Imeka, the leading neuroimaging company combining diffusion imaging and AI to map white matter integrity, today announced a collaboration with Atara Biotherapeutics, Inc. to utilize Imeka’s novel biomarker technology in a Phase 2 clinical study of patients with progressive forms of multiple sclerosis (MS).

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced the expansion of the company’s existing strategic collaboration with Pfizer.

LumiraDx, a next-generation point of care diagnostics company, announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.

Critically ill patients treated with ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) within 60 hours of ICU admission experienced a survival rate double that of patients treated after being in the ICU for 60 or more hours, according to a newly released study.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has expanded its ongoing collaboration agreement with Merck to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis (NASH).